Почетна › Карцином на јајниците › Мичиген › Detroit
Клинички испитувања за Карцином на јајниците во Detroit, MI
26 студии за Карцином на јајниците бараат учесници на локации во и околу Detroit (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
The Vanguard Study: Testing a New Way to Screen for Cancer
Се регрутираДобредојдени се здрави волонтери
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Се регрутираФаза 2/3
- Henry Ford Hospital, Detroit
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Се регрутираФаза 1/2
- Research Site, Detroit
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Се регрутираНабљудувачка студија
- Henry Ford Health, Detroit
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Се регрутираФаза 1/2
- Karmanos Cancer Institute, Detroit
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Се регрутираФаза 2
- Site 0101 - Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Се регрутираФаза 1/2
- Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Се регрутираФаза 3
- Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Се регрутираФаза 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Се регрутираФаза 2
- Karmanos Cancer Institute - Detroit /ID# 277085, Detroit
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Се регрутираФаза 3
- Henry Ford Cancer - Detroit, Detroit
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Се регрутираФаза 2
- Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Се регрутираФаза 1
- Karmanos Cancer Institiute, Detroit
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Се регрутираФаза 3
- Karmanos Cancer Institute, Detroit
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Се регрутираФаза 1
- Karmanos Cancer Institute, Detroit
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Се регрутираФаза 1
- Karmanos Cancer Center, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Се регрутираФаза 3
- Henry Ford Health Saint John Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Се регрутираФаза 1/2
- Karmanos Cancer Institute, Detroit
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Се регрутираФаза 1
- Karmanos Cancer Institute, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Се регрутираФаза 1/2
- Henry Ford Health Hospital, Detroit
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Се регрутираФаза 2
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Се регрутираФаза 2
- Karmanos Cancer Institute - Detroit /ID# 272112, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Се регрутираФаза 1/2
- Karmanos Cancer Institute, Detroit
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Се регрутираФаза 1
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Се регрутираФаза 1/2
- Karmanos Cancer Institute, Detroit
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Се регрутираФаза 1
- Karmanos Cancer Institute, Detroit
Испитувања за Карцином на јајниците во други градови
- Houston, TX89 студии
- New York City, NY69 студии
- Boston, MA61 студија
- Los Angeles, CA50 студии
- Nashville, TN49 студии
- Arlington, VA46 студии
- Philadelphia, PA44 студии
- Columbus, OH39 студии
- St. Louis, MO38 студии
- Chicago, IL36 студии
- San Antonio, TX31 студија
- Cleveland, OH30 студии
Други студии во Detroit
- Рак на бели дробови со не-мали клетки44 студии
- Рак на дојка33 студии
- Рак (сите типови)29 студии
- Колоректален карцином26 студии
- Метастатски карцином24 студии
- Рак на простата22 студии
- Рак на ендометриумот21 студија
- Рак на бели дробови20 студии
- Множен миелом19 студии
- Рак на стомакот16 студии
- Сквамозноклеточен карцином на глава и врат15 студии
- Акутна миелоидна леукемија14 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.